- ISIN
- US7530181004
- CUSIP
- 753018100
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 30, 2021
Highlights
- Market Cap
- $139.08M
- Enterprise Value
- $134.84M
- EPS (TTM)
- -$0.29
- Total Revenue (TTM)
- $1.46M
- Gross Profit (TTM)
- $1.05M
- EBITDA (TTM)
- -$34.21M
- Year Range
- $0.39 - $3.87
- Target Price
- $15.67
- ROA (TTM)
- -56.75%
- ROE (TTM)
- -103.65%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RANI Performance Chart
Rani Therapeutics Holdings, Inc. (RANI) is down 42.8% since the beginning of the year. At $1 per share, RANI is trading 80.0% below its 52-week high of $4.
Loading charts...
Returns By Period
Rani Therapeutics Holdings, Inc. (RANI) has returned -42.76% so far this year and 54.39% over the past 12 months.
Rani Therapeutics Holdings, Inc.
- 1D
- -1.24%
- 1M
- -27.79%
- YTD
- -42.76%
- 6M
- -48.14%
- 1Y
- 54.39%
- 3Y*
- -43.61%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
RANI Monthly Returns History
Based on dividend-adjusted daily data since Jul 30, 2021, RANI's average daily return is +0.10%, while the average monthly return is +2.32%. At this rate, an investment would double in approximately 2.5 years.
Historically, 40% of months were positive and 60% were negative. The best month was Oct 2025 with a return of +340.2%, while the worst month was May 2025 at -49.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, RANI closed higher 45% of trading days. The best single day was Oct 17, 2025 with a return of +248.3%, while the worst single day was Jul 15, 2025 at -38.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.37% | 13.22% | -46.36% | 20.84% | 7.08% | -18.73% | -42.76% | ||||||
| 2025 | 1.46% | 10.07% | -17.65% | -11.90% | -49.62% | -8.10% | 4.28% | -4.81% | -2.02% | 340.18% | -27.27% | -15.63% | -1.46% |
| 2024 | 4.22% | 8.09% | -16.84% | 105.14% | -13.79% | -30.91% | -25.53% | 13.07% | -32.50% | 6.02% | -11.79% | -32.18% | -58.73% |
| 2023 | -6.95% | 14.75% | -18.10% | -8.91% | -13.19% | 0.98% | 3.88% | -11.21% | -42.76% | -9.89% | 1.02% | 67.68% | -43.73% |
| 2022 | 26.79% | -19.49% | -19.11% | -9.41% | -6.79% | -9.39% | 8.91% | -20.89% | 7.64% | -36.33% | 35.74% | -28.74% | -63.91% |
| 2021 | -2.31% | 67.64% | -3.36% | 29.07% | 28.87% | -44.84% | 45.20% |
Benchmark Metrics
Rani Therapeutics Holdings, Inc. has an annualized alpha of 10.04%, beta of 1.36, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since July 30, 2021.
- This stock participated in 168.50% of S&P 500 Index downside but only -40.95% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 10.04%
- Beta
- 1.36
- R²
- 0.02
- Upside Capture
- -40.95%
- Downside Capture
- 168.50%
Return for Risk
Risk / Return Rank
RANI ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Rani Therapeutics Holdings, Inc. (RANI) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RANI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.83 | ||
| Sortino ratioReturn per unit of downside risk | +0.41 | ||
| Omega ratioGain probability vs. loss probability | 1.41 | 1.37 | +0.04 |
| Calmar ratioReturn relative to maximum drawdown | 0.74 | 2.78 | -2.05 |
| Martin ratioReturn relative to average drawdown | 1.13 | 12.44 | -11.31 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Rani Therapeutics Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Rani Therapeutics Holdings, Inc. was 98.83%, occurring on Jul 16, 2025. The portfolio has not yet recovered.
The current Rani Therapeutics Holdings, Inc. drawdown is 97.79%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -98.83%Jul 2025 | 3y 8mo | — | 4y 7moNov 2021 - now |
2021 bear market2021 | -25.36%Aug 2021 | 4d | 28d | 1mo 2dAug 2021 - Sep 2021 |
2021 bear market2021 | -24.92%Oct 2021 | 22d | 21d | 1mo 13dSep 2021 - Oct 2021 |
2021 correction2021 | -17.37%Nov 2021 | 3d | 9d | 12dNov 2021 - Nov 2021 |
2021 pullback2021 | -9.95%Oct 2021 | 0s | 4d | 4dOct 2021 - Nov 2021 |
Drawdown Indicators
| RANI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.83% | -56.78% | -42.05% |
Max Drawdown (1Y)Largest decline over 1 year | -74.22% | -9.10% | -65.12% |
Max Drawdown (3Y)Largest decline over 3 years | -94.78% | -18.90% | -75.88% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.79% | -1.80% | -95.99% |
Average DrawdownAverage peak-to-trough decline | -80.64% | -10.71% | -69.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 48.29% | 2.03% | +46.26% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Rani Therapeutics Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Rani Therapeutics Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RANI relative to other companies in the Biotechnology industry. Currently, RANI has a P/S ratio of 52.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RANI in comparison with other companies in the Biotechnology industry. Currently, RANI has a P/B value of 4.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RANI
Add Rani Therapeutics Holdings, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RANI